‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis

References

• Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 Sep;5(9):691–706. PubMed PMID: 28822787; PubMed Central PMCID: PMCPMC5573769. eng.
   PubMed Web of Science ®Google Scholar
• Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015 Apr;135(4):896–902. PubMed PMID: 25441637; eng.
   PubMed Web of Science ®Google Scholar
• Chen H, Gould MK, Blanc PD, et al. Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J Allergy Clin Immunol. 2007 Aug;120(2):396–402. PubMed PMID: 17561244.
   PubMed Web of Science ®Google Scholar
• Sadatsafavi M, McTaggart-Cowan H, Chen W, et al. Quality of life and asthma symptom control: room for improvement in care and measurement. Value Health. 2015 Dec;18(8):1043–1049. PubMed PMID: 26686789; eng.
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001 Aug;108(2):184–190. PubMed PMID: 11496232; eng.
   PubMed Web of Science ®Google Scholar
• Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med. 2006 Nov;100(11):1907–1917. PubMed PMID: 16949266; eng.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014 Jan;13(1):Cd003559. PubMed PMID: 24414989; eng.
   Google Scholar
• Alhossan A, Lee CS, MacDonald K, et al. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1362–1370 e2. PubMed PMID: 28351783.
   PubMed Web of Science ®Google Scholar
• MacDonald KM, Kavati A, Ortiz B, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008–2018. Expert Rev Clin Immunol. 2019 May;15(5):553–569. PubMed PMID: 30763137.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Turk F, Leighton T, et al. Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J Med Econ. 2007 Jan 01;10(3):285–296.
   Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004 Jan;113(1):59–65. PubMed PMID: 14713908.
   PubMed Web of Science ®Google Scholar
• Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006 Mar;117(3):549–556. PubMed PMID: 16522452.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992 Feb;47(2):76–83. PubMed PMID: 1549827; PubMed Central PMCID: PMCPMC463574.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009 Nov;103(11):1633–1642. PubMed PMID: 19619998.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Perry R, Papadopoulos NG, et al. The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. Clin Transl Allergy. 2019:9:21. PubMed PMID: 30962876; PubMed Central PMCID: PMCPMC6436213.
   PubMed Web of Science ®Google Scholar
• Roche N, Campbell JD, Krishnan JA, et al. Quality standards in respiratory real-life effectiveness research: the REal life evidence assessment tool (RELEVANT): report from the respiratory effectiveness group-european academy of allergy and clinical immunology task force. Clin Transl Allergy. 2019:9:20. PubMed PMID: 30962875; PubMed Central PMCID: PMCPMC6436229.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000 Apr 19;283(15):2008–2012. PubMed PMID: 10789670.
   PubMed Web of Science ®Google Scholar
• Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013;4:863. PubMed PMID: 24324449; eng.
   PubMed Web of Science ®Google Scholar
• Cohen J. A power primer. Psychol Bull. 1992 Jul;112(1):155–159. PubMed PMID: 19565683.
   PubMed Web of Science ®Google Scholar
• Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014 Nov 10;72(1):39.
   PubMedGoogle Scholar
• Cheung MW, Vijayakumar RA. Guide to conducting a meta-analysis. Neuropsychol Rev. 2016 Jun;26(2):121–128. PubMed PMID: 27209412.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–188. PubMed PMID: 3802833.
   PubMedGoogle Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13;315(7109):629–634. PubMed PMID: 9310563; PubMed Central PMCID: PMCPMC2127453.
   PubMed Web of Science ®Google Scholar
• Harbord RM, Harris RJ, Sterne JAC. Updated tests for small-study effects in meta-analyses [Report]. Stata J. 2009;9(2):197–210. English.
   Web of Science ®Google Scholar
• Sterne JAC, Harbord RM. Funnel plots in meta-analysis. Stata J. 2004;4(2):127–141.
   Web of Science ®Google Scholar
• Adachi M, Kozawa M, Yoshisue H, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term post-marketing study in Japan. Respir Med. 2018 Aug;141:56–63. PubMed PMID: 30053973.
   PubMed Web of Science ®Google Scholar
• Alfarroba S, Videira W, Galvao-Lucas C, et al. Clinical experience with omalizumab in a Portuguese severe asthma unit. Rev Port Pneumol. 2014 Mar-Apr;20(2):78–83. PubMed PMID: 24525397.
   PubMedGoogle Scholar
• Ancochea J, Chivato T, Casan P, et al. Profile of patients treated with omalizumab in routine clinical practice in Spain. Allergol Immunopathol (Madr). 2014 Mar-Apr;42(2):102–108. PubMed PMID: 23267505.
   PubMed Web of Science ®Google Scholar
• Barnes N, Menzies-Gow A, Mansur AH, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013 Jun;50(5):529–536. PubMed PMID: 23574000; PubMed Central PMCID: PMCPMC3681088.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011 May;66(5):671–678. PubMed PMID: 21255035.
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Canvin J, Peachey G, et al. Healthcare resource utilization in patients receiving omalizumab for allergic asthma in a real-world setting. Biol Ther. 2014 Dec;4(1–2):57–67. PubMed PMID: 25371373; PubMed Central PMCID: PMCPMC4254868.
   PubMedGoogle Scholar
• Braunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013 Aug;107(8):1141–1151. PubMed PMID: 23721684.
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Chlumsky J, Peachey G, et al. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol. 2013 Dec 4;9(1):47. PubMed PMID: 24305549; PubMed Central PMCID: PMCPMC3879326.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Camiciottoli G, Bonavia M, et al. Italian real-life experience of omalizumab. Respir Med. 2010 Oct;104(10):1410–1416. PubMed PMID: 20483574.
   PubMed Web of Science ®Google Scholar
• Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci. 2011 Sep;180(3):637–641. PubMed PMID: 21557095.
   PubMed Web of Science ®Google Scholar
• Gouder C, West LM, Montefort S. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. Int J Clin Pharm. 2015 Feb;37(1):36–43. PubMed PMID: 25394832.
   PubMed Web of Science ®Google Scholar
• Humbert M, Taille C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018 May;51(5):1702523. PubMed PMID: 29545284; PubMed Central PMCID: PMCPMC6383600.
   Web of Science ®Google Scholar
• Kawamatawong T, Poachanukoon O, Boonsiri C, et al. Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: a real-life experience. Asian Pac J Allergy Immunol. 2018 Dec;36(4):238–243. PubMed PMID: 29161053.
   PubMed Web of Science ®Google Scholar
• Kelmenson DA, Kelly VJ, Winkler T, et al. The effect of omalizumab on ventilation and perfusion in adults with allergic asthma. Am J Nucl Med Mol Imaging. 2013;3(4):350–360. PubMed PMID: 23901360; PubMed Central PMCID: PMCPMC3715779
   PubMedGoogle Scholar
• Korn S, Thielen A, Seyfried S, et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009 Nov;103(11):1725–1731. PubMed PMID: 19515548.
   PubMed Web of Science ®Google Scholar
• Kuprys-Lipinska I, Majak P, Molinska J, et al. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulm Med. 2016 Apr 26;16(1):61. PubMed PMID: 27117315; PubMed Central PMCID: PMCPMC4847261.
   PubMed Web of Science ®Google Scholar
• Maltby S, Gibson PG, Powell H, et al. Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD. Chest. 2017 Jan;151(1):78–89. PubMed PMID: 27742181.
   PubMed Web of Science ®Google Scholar
• Molimard M, de Blay F, Didier A, et al. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med. 2008 Jan;102(1):71–76. PubMed PMID: 17920257.
   PubMed Web of Science ®Google Scholar
• Niven RM, Saralaya D, Chaudhuri R, et al. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open. 2016 Aug 9;6(8):e011857. PubMed PMID: 27507234; PubMed Central PMCID: PMCPMC4985870.
   PubMed Web of Science ®Google Scholar
• Nygaard L, Henriksen DP, Madsen H, et al. Appropriate selection for omalizumab treatment in patients with severe asthma? Eur Clin Respir J. 2017;4(1):1359477. PubMed PMID: 28815007; PubMed Central PMCID: PMCPMC5553102.
   PubMed Web of Science ®Google Scholar
• Ozgur ES, Ozge C, Ilvan A, et al. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma. J Asthma. 2013 Aug;50(6):687–694. PubMed PMID: 23557459.
   PubMed Web of Science ®Google Scholar
• Paganin F, Mangiapan G, Proust A, et al. Lung function parameters in omalizumab responder patients An interesting tool? Allergy. 2017 Dec;72(12):1953–1961. PubMed PMID: 28517027.
   PubMed Web of Science ®Google Scholar
• Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel. J Asthma. 2012 Feb;49(1):78–82. PubMed PMID: 22149205.
   PubMed Web of Science ®Google Scholar
• Rubin AS, Souza-Machado A, Andradre-Lima M, et al. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma. 2012 Apr;49(3):288–293. PubMed PMID: 22356355.
   PubMed Web of Science ®Google Scholar
• Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J. 2012 Oct;6(4):215–227. PubMed PMID: 21740532.
   PubMed Web of Science ®Google Scholar
• Subramaniam A, Al-Alawi M, Hamad S, et al. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland. QJM. 2013 Jul;106(7):631–634. PubMed PMID: 23550166.
   PubMed Web of Science ®Google Scholar
• Sweeney J, Brightling CE, Menzies-Gow A, et al. Clinical management and outcome of refractory asthma in the UK from the British thoracic society difficult asthma registry. Thorax. 2012 Aug;67(8):754–756. PubMed PMID: 22581823; PubMed Central PMCID: PMCPMC3402747.
   PubMed Web of Science ®Google Scholar
• Tajiri T, Niimi A, Matsumoto H, et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol. 2014 Oct;113(4):470–5 e2. PubMed PMID: 24994694.
   PubMed Web of Science ®Google Scholar
• Tzortzaki EG, Georgiou A, Kampas D, et al. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean “real-life” experience. Pulm Pharmacol Ther. 2012 Feb;25(1):77–82. PubMed PMID: 22155001.
   PubMed Web of Science ®Google Scholar
• Vennera Mdel C, Perez De Llano L, Bardagi S, et al. Omalizumab therapy in severe asthma: experience from the Spanish registry–some new approaches. J Asthma. 2012 May;49(4):416–422. PubMed PMID: 22443408; eng.
   PubMed Web of Science ®Google Scholar
• Vieira T, de Oliveira JF, da Graca Castel-branco M. Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal. Allergol Immunopathol (Madr). 2014 Jan-Feb;42(1):3–10. PubMed PMID: 23253691.
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Muhlig S, Klotsche J, et al. Omalizumab versus ‘usual care’: results from a naturalistic longitudinal study in routine care. Int Arch Allergy Immunol. 2012;159(1):83–93. PubMed PMID: 22573022.
   PubMed Web of Science ®Google Scholar
• Carvalho-Pinto RM, Agondi RC, Giavina-Bianchi P, et al. Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control. J Bras Pneumol. 2017 Nov-Dec;43(6):487–489. PubMed PMID: 29340498; PubMed Central PMCID: PMCPMC5792049.
   PubMed Web of Science ®Google Scholar
• Caminati M, Senna G, Chieco Bianchi F, et al. Omalizumab management beyond clinical trials: the added value of a network model. Pulm Pharmacol Ther. 2014 Oct;29(1):74–79. PubMed PMID: 24508951.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma. 2012 Oct;49(8):843–848. PubMed PMID: 22954018.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Fiorino I, Taurino M, et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study. Respir Med. 2017 Sep;130:55–60. PubMed PMID: 29206634.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Zureik M, Aubier M, et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013 Feb 1;143(2):398–405. PubMed PMID: 23505637.
   PubMed Web of Science ®Google Scholar
• Lopez Tiro JJ, Contreras EA, Del Pozo ME, et al. Real life study of three years omalizumab in patients with difficult-to-control asthma. Allergol Immunopathol (Madr). 2015 Mar-Apr;43(2):120–126. PubMed PMID: 24780091.
   PubMed Web of Science ®Google Scholar
• Mansur AH, Srivastava S, Mitchell V, et al. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir Med. 2017 Mar;124:36–43. PubMed PMID: 28284319.
   PubMed Web of Science ®Google Scholar
• Novelli F, Latorre M, Vergura L, et al. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015 Apr;31:123–129. PubMed PMID: 25281265.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Gallelli L, Romeo P, et al. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma. Int J Clin Pharmacol Ther. 2011 Dec;49(12):713–721. PubMed PMID: 22122813.
   PubMed Web of Science ®Google Scholar
• Sposato B, Scalese M, Latorre M, et al. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience. Respir Med. 2016 Oct;119:141–149. PubMed PMID: 27692136.
   PubMed Web of Science ®Google Scholar
• Tat TS, Cilli A. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma. Ann Allergy Asthma Immunol. 2016 Nov;117(5):546–549. PubMed PMID: 27788886.
   PubMed Web of Science ®Google Scholar
• Higgins JPT. Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 2008;37(5):1158–1160.
   PubMed Web of Science ®Google Scholar
• Ben-Shoshan M. Omalizumab: not only for asthma. Recent Pat Inflamm Allergy Drug Discov. 2008 Nov;2(3):191–201. PubMed PMID: 19076009; eng.
   PubMedGoogle Scholar
• Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (Spontaneous) Urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. 2019 Jan 1;155(1):29–38. PubMed PMID: 30427977; PubMed Central PMCID: PMCPMC6439579.
   PubMed Web of Science ®Google Scholar